OPZELURA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, UK.

Active ingredients

The drug OPZELURA contains one active pharmaceutical ingredient (API):

1	Ruxolitinib UNII 82S8X8XX8H - RUXOLITINIB
	Ruxolitinib is a selective inhibitor of the Janus Associated Kinases (JAKs) JAK1 and JAK2. These mediate the signalling of a number of cytokines and growth factors that are important for haematopoiesis and immune function.
	Read more about Ruxolitinib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
OPZELURA Cream	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D11AH09		D Dermatologicals → D11 Other dermatological preparations → D11A Other dermatological preparations → D11AH Agents for dermatitis, excluding corticosteroids
Discover more medicines within D11AH09

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1888331
FR	Base de données publique des médicaments	68279528
IT	Agenzia del Farmaco	050666015
LT	Valstybinė vaistų kontrolės tarnyba	1097002, 1097302
US	FDA, National Drug Code	50881-007